Finn
GMED Medical Devices · Spine surgery · Robotics · Medical devices · Thesis updated August 11, 2026

Margin gains drive the spine story despite shifting sales mix

01 Running thesis

Share gains with a higher execution bar

Globus is proving it can integrate big acquisitions while lifting margins. Q2 2026 made this clear when adjusted EBITDA margins expanded 740 basis points. The core U.S. Spine business also grew 7%, marking its fifth straight quarter of above-market gains.

The bull case is that Globus is building a closed system for spine surgery. Its robots and navigation tools help place implants. The implants then create repeat sales each time a surgeon uses the system. The new patient-specific script platform adds another piece to that system, because it ties custom implants into the same technology stack.

The bear case focuses on near-term revenue gaps. Enabling Technologies fell 26% in Q2 as more hospitals chose leases instead of buying systems upfront. Nevro is also facing a longer turnaround, with a 14% sales decline and trial volume recovery pushed to late 2026.

Finn’s view remains positive. The company has strong financial health and is generating cash faster than planned. The stock still needs proof that the lease strategy will drive enough implant pull-through to offset lower upfront system sales.

Aug 2026▲Q2 2026 results showed major margin gains with adjusted EBITDA margin expanding 740 basis points. Management raised full-year EPS guidance to $4.95 to $5.05.
May 2026▲Q1 confirmed the late-2025 rebound. U.S. Spine grew 10% again, Enabling Technologies rose to $26.9 million, and management lifted 2026 non-GAAP EPS guidance to $4.70 to $4.80.
May 2026→The Q1 2026 10-Q confirmed $759.9 million of total net sales and $67.2 million of U.S. Nevro sales. It also said risk factors had no material changes from the 2025 Form 10-K.
Feb 2026▲Q4 2025 strengthened the case that acquisition risk had fallen. Globus said it had actioned $200 million of NuVasive synergies ahead of plan and that Nevro became accretive 15 months earlier than first expected.
Nov 2025▲Q3 2025 was a major beat-and-raise quarter. Total net sales rose 22.9%, U.S. Spine grew 10%, and free cash flow reached a record non-GAAP $213.9 million.
Aug 2025▲Q2 2025 showed the supply chain issues from Q1 were easing. U.S. Spine grew 7.4% on a day-adjusted basis, and Enabling Technologies recovered from Q1, though sales cycles stayed longer.
02 Business model

Implants pulled by robots

Globus makes money by selling implants, tools, biologics, trauma products, neuromonitoring services, and chronic pain stimulation systems. The key profit engine is spine implants. These are used in surgeries where doctors stabilize or repair the spine.

Its Enabling Technologies business sells or places imaging, navigation, and robotic systems such as ExcelsiusGPS. These systems are expensive capital equipment, so sales can jump around by quarter. The strategic goal is not only the robot sale. The bigger prize is implant pull-through, which means more Globus implants used in each procedure because the surgeon works inside the Globus system.

The company also has supply chain control. The internal view says about 95% of production is based in the U.S., which can help with quality, speed, and tariff exposure. That does not remove risk, but it gives Globus more control than a device maker that depends heavily on overseas production.

Nevro extends the model into chronic pain care. Its spinal cord stimulation systems treat pain with electrical pulses rather than spine surgery. If Globus can fix Nevro’s sales base, it could capture more of the patient journey before and after surgery.

03 Product portfolio

The tools in the system

Growth engine

U.S. Spine implants

This is the core engine. Products include expandable spacers, MIS screws, lateral and ACDF platforms, and fixation systems.

Option

ExcelsiusGPS and Enabling Technologies

These are robotic, imaging, and navigation systems used to guide surgery. Sales can be uneven, but each placement can support future implant use.

Option

Script patient-specific implants

Globus received 510(k) clearance for a patient-specific spacer and rod system. The early question is whether surgeons adopt it beyond a small set of complex cases.

Steady

Trauma and NSO

This smaller group includes trauma, neurosurgery, and orthopedic products. Management has said underlying trauma demand is strong, though integration work has caused some disruption.

Option

Nevro neuromodulation

Nevro sells high-frequency spinal cord stimulation systems for chronic pain. It is currently facing sales declines as the company works to restructure the business for profitable growth.

04 Business segments

Mostly musculoskeletal sales

Musculoskeletal Solutions96%growing fast
Enabling Technologies4%growing fast

The mix uses early 2026 net sales trends. Globus reports one reportable segment, but it describes two product and service categories: Musculoskeletal Solutions and Enabling Technologies.

05 Risk factors

What could break the story

U.S. Spine growth slows

High impact · Medium odds

U.S. Spine grew 7% in Q2, making it five straight quarters of above-market growth. If the gains came mainly from recruiting reps or easy account wins, growth could slow as comparisons get tougher.

We watchQuarterly U.S. Spine growth, plus management comments on rep recruiting, cross-selling, and robotic pull-through.

Lease strategy creates a sales gap

Medium impact · Medium odds

Management is shifting more Enabling Technologies deals toward leases and rentals, which caused a 26% revenue drop in Q2. That may speed system placements, but it reduces upfront revenue. The long-term payoff depends on enough implant revenue following those placements.

We watchEnabling Technologies revenue, new system placements, and the mix of sales versus leases and rentals.

Nevro revenue does not trough

Medium impact · Medium odds

Nevro sales declined 14% in Q2. Management now expects trial volumes to begin recovering late in Q4 2026. A further delay would hurt confidence in the turnaround and the overall value of the deal.

We watchNevro quarterly sales, sales force hiring, and any change to the expected late-2026 recovery.

Margins stop improving

High impact · Low odds

Management raised 2026 non-GAAP EPS guidance to $4.95 to $5.05 following massive Q2 margin expansion. That signals deep confidence in cost savings and manufacturing gains, but investors will punish a miss because the stock now expects near-perfect execution.

We watchAdjusted gross margin, non-GAAP EPS guidance, and updates on NuVasive and Nevro synergy capture.

Robotics competition tightens

Medium impact · Medium odds

Spine surgery is competitive, and robotics is a key battleground. Globus has an integrated system, but rivals can still compete on surgeon relationships, pricing, and hospital contracts. If new systems reduce Globus placements, implant pull-through could weaken.

We watchExcelsiusGPS placement trends, hospital contract wins, and comments about competitive pricing.
06 Quick answers

In one breath

What does Globus Medical actually sell?

Globus sells medical devices for spine surgery, trauma care, neurosurgery, and chronic pain. Its main products are spine implants and the robotic and navigation systems that help surgeons place them.

Why does the robot matter if implants make most of the money?

The robot can make surgeons more likely to use Globus implants during procedures. That is called implant pull-through, which means one system placement can lead to repeat implant sales over time.

What is the main reason investors are watching Nevro?

Nevro moved to earnings accretion faster than planned, but its sales are still uneven. Investors need to see trial volumes and revenue stabilize in late 2026 before treating the deal as fully fixed.

Is Globus Medical mainly a U.S. company?

Yes. Most of its sales come from the U.S., though international markets still make up a meaningful percentage of total net sales.

Get started with Finn today